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Abstract
Background: Our previous studies have identified that miR-125b was overexpressed in type II endometrial
carcinoma (EC) cells compared with type I using microRNAs microarray. Although recent studies have shown the
important role of miR-125b in several tumors and overexpression of miR-125b in advanced EC, its function in this
disease has not yet been defined. In the present study, we tried to confirm the result of microRNAs microarray and
further investigated the functions of miR-125b in EC, and tried to find new downstream targets of miR-125b.
Methods: Differential expression of miR-125b was detected between type II EC cells (KLE, AN3CA) with ER negative
and type I EC cells (ishikawa, RL95-2) with ER positive by qRT-PCR and northern blotting. The effects of miR-125b of
on proliferation, migration, and target protein expression were evaluated by CCK8 assay, wound healing assay,
transwell migration assay, western blotting, and Tumorigenicity assays in nude mice. In addition, luciferase reporter
plasmid was constructed to demonstrate the direct target of miR-125b.
Results: MiR-125b was overexpressed in type II EC cells compared with type I. Exogenous miR-125b expression
increased proliferation and migration of ishikawa cells and abrogating expression of miR-125b suppressed
proliferation, and migration of AN3CA cells in vitro. In addition, in vivo tumor formation assay confirmed that
forced miR-125b expression promoted proliferation potential of ishikawa cells, and tumor suppressor gene Tumor
Protein 53-Induced Nuclear Protein 1 (TP53INP1) was identified to be the direct target of miR-125b.
Conclusions: TP53INP1 was newly identified to be the direct downstream target of miR-125b. MiR-125b, which
was overexpressed in type II EC cells compared with type I, contributes to malignancy of type II EC possibly
through down-regulating TP53INP1.
Background
Endometrial carcinoma (EC) is one of the most com-
mon gynecologic malignancies and it is totally classified
into two subtypes referred to as type I and type II EC
[1]. Type I EC, occurring in ~85% of patients, often dis-
plays ER positive. Tumors with this type tend to be well
differentiated, of low grade and good prognosis. In con-
trast, type II, consisting mostly of serous and clear cell
carcinoma, typically arises in atrophic endometrium via
a mechanism unrelated to estrogen exposure. This type
is usually ER negative, and poorly differentiated, of high
grade and poor prognosis. Although type II ECs account
for approximately 15% of cases, they are responsible for
about 50% of all relapses [2]. Great progress was made
in the therapies of type II EC, but its 5-year survival
rate is still less than 15%. Molecular mechanisms
explaining the development and progression of type II
EC are still unknown.
MicroRNAs are ~22 nucleotide (nt) non-coding RNAs
that function as sequence-specific regulators of gene
expression through translational repression and/or tran-
script cleavage [3-6]. Since the roles and functions of
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endogenously expressed microRNAs were first described
in C. elegans in 1993 [7], more and more studies have
shown that microRNAs play key roles in cellular pro-
cesses of differentiation, proliferation, apoptosis and
metabolic homeostasis. MicroRNAs profiles have shown
that there was much microRNAs expression variation
across the different subtypes and stages of carcinogen-
esis, with data indicating that they may play vital roles
in the initiation and progression of human malignancies
[8,9]. In cancer tissues, microRNAs appear to be dysre-
gulated such that those with tumor-suppressor activity
are abrogated, while those that are overexpressed may
function as oncogenes promoting proliferation, migra-
tion and invasion, and repressing apoptosis respectively.
Recent data showed that overexpression or lack of
expression of certain specific microRNAs were corre-
lated to metastatic and aggressive clinical phenotypes
[10-12]. It was demonstrated that miR-125b was dysre-
gulated in many tumors such as prostate cancer [13],
leukemia [14,15] liver cancer [16], and oligodendroglial
tumors [17]. In addition, miR-125b has been demon-
strated to mediate the proliferative effects through
down-regulating p53 [18], pro-apoptotic Bcl-2 antago-
nist killer 1 (Bak1) [19], and Bcl-2 modifying factor
(Bmf) [20]. It has also been proved to be one of etiologic
factors of leukemia [21]. Taken together, these observa-
tions suggest that miR-125b may play a vital role in the
initiation and progression of cancers.
In our previous work, we chose well-differentiated EC
cells (ishikawa, RL95-2) with ER positive and metastatic
EC cells (KLE, AN3CA) with ER negative as models of
type I and type II EC, respectively. Using microRNAs
microarray, we found that miR-125b was significantly
overexpressed in ER-negative cells, especially in AN3CA
cells, when compared with ER-positive cells. Although
recent studies have shown the important role of miR-
125b in several tumors and overexpression of miR-125b
in advanced ECs [22], its function in this disease has
not yet been defined. The findings promoted us to
hypothesize that miR-125b may contribute to malig-
nancy of type II EC. In the present study, we confirmed
the result of microRNAs microarray, and further investi-
gated the functions of miR-125b in EC and found new
downstream targets of miR-125b.
Methods
Reagents
Four synthetic, chemically modified short single- or
double-stranded RNA oligonucleotides: miR-125b
mimics (miR-125bm), miR-125b mimics negative con-
trol (miR-125bm NC), miR-125b inhibitors (miR-125bi)
and miR-125b inhibitors negative control (miR-125bi
NC) were synthesized from Shanghai GenePharma Co.,
Ltd. Commercial miR-125b expression plasmid and
control vector were purchased from Shanghai Gene-
Chem Co., Ltd.
Cell culture and transfection
Ishikawa, RL95-2, KLE, and AN3CA cells were obtained
from American Type Culture Collection (ATCC, Mana-
ssas, Va) and were maintained DMEM/F12 media
(11030; Gibco, Auckland, NZ) supplemented with 10%
FBS (S1810; Biowest, Nuaillé, France), 100 units/ml
penicillin, and 100 μg/ml streptomycin. All cells were
grown in sterile conditions at 37°C in a humidified
atmosphere of 5% CO2 and 95% air. Before the experi-
ment, the ER expressions of these cells were confirmed
by immunocytochemistry. Cells were seeded in 6-well
plates at 70-80% confluence and grown overnight before
transfection. Transfection of AN3CA cells (or ishikawa
cells) with miR-125bi (or miR-125bm) or counterpart
negative control using the lipfectamine2000 transfection
reagent (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s instructions. The total experiments
were classified into three groups, which were miR-
125bm (or miR-125bi) group, miR-125bm NC (or miR-
125bi NC) group, and untransfected group.
RNA isolation and qRT- PCR
Total RNA was isolated from cultured cells with Tri-
reagent (TR118; Molecular Research Center, Cincinnati,
OH, USA) according to manufacturer’s instructions.
QRT-PCR analyses for microRNAs were performed
using TaqMan microRNA assays. In brief, all reagents
and primers were obtained from Applied Biosystems.
U6 snRNA served as an endogenous control for normal-
ization. Reverse transcriptase reactions and real-time
PCR were performed according to the manufacturer’s
protocols. CDNA was made from 50 ng total RNA from
each sample using the microRNA TaqMan Reverse
Transcription Kit and miR-125b specific reverse tran-
scription primer. QRT-PCR reactions were performed in
triplicate on a RealPlex4 real-time PCR detection system
from Eppendorf Co. LTD (Germany), with cycle thresh-
old values determined using the manufacturer’s soft-
ware. Relative expression of miR-125b, relative to U6
snRNA, was calculated using the 2-delta delta CT method.
Northern blotting analysis
All steps of Northern blotting were performed as pre-
viously described [20]. For all groups, 20 μg of good
quality total RNA was subjected to electrophoresis on a
15% Urea-PAGE gel, and transferred to a Hybond N+
nylonmembrane (Amersham, Freiburg, Germany). After
being UV-cross-linked and baked at 50°C for 30 min,
the membrane was prehybridized at 42°C for 4 h and
then hybridized with the miR-125b anti-sense StarFire
probe, 5’-TCACAAGTTAGGGTCTCAGGGA-3’ (IDT,
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Coralville, IA), to detect the 22-nt miRNA-125b frag-
ments according to the instruction of the manufacturer.
After washing, membranes were exposed for 20 ~ 40 h
to Kodak XAR-5 films (Sigma-Aldrich). As a positive
control, all membranes were hybridized with a human
U6 snRNA probe, 5’-GCAGGGGCCATGCTAATCTTC
TCTGTATCG-3’. Exposure times for the U6 control
probe varied from 15-30 min.
SiRNA targeting
To inhibit expression of endogenous TP53INP1, we
designed and prepared HPLC- purified TP53INP1
siRNA (sense: 5’-TCAGCCTCTGGAACAT-3’; anti-
sense: 5’-ATGTTCCAGAGGCTGA-3’) and, a scrambled
siRNA with no homology to any known human mRNA
was used as negative control (sense: 5’-CTGTTAAA
AATCCAGG-3’; anti-sense: 5’-CCTGGATTTTTAA
CAG-3’) according to the sequence of the TP53INP1
gene. SiRNA oligonucleotide duplexes were synthesized
by Genephama Biotech (Shanghai, China).
Cell proliferation assay
Cells at 12 h post-transfection were seeded in 96-well
plates at 2500 cells/well. After that, cell proliferation
was evaluated using the CCK8 (C0038, Beyotime Inst
Biotech, China) according to manufacturer’s instruc-
tions. Briefly, 10 μl of CCK8 solution was added to the
culture medium, and incubated for additional 3 h. The
absorbance was determined at 450 nm wavelength with
a reference wavelength of 630 nm.
Wound healing assay
Cells (6 × 106 per well) at 12 h post-transfection were
seeded in six-well plates and allowed to adhere for 24 h.
Confluent monolayer cells were scratched by a 200 μl
pipette tip and then washed three times with 1 × PBS to
clear cell debris and suspension cells. Fresh serum-free
medium was added, and the cells were allowed to close
the wound for 48 h. Photographs were taken at 0, 24,
and 48 h at the same position of the wound.
Transwell migration assay
Cells (2 × 105) were resuspended in 200 μl of serum-
free medium and seeded on the top chamber of the 8
μm pore, 6.5 mm polycarbonate transwell filters (Corn-
ing). The full medium (600 μl) containing 10% FBS
was added to the bottom chamber. The cells were
allowed to migrate for 24 h at 37°C in a humidified
incubator with 5% CO2. The cells attached to the
lower surface of membrane were fixed in 4% parafor-
maldehyde at room temperature for 30 min and
stained with 4,6-diamidino-2-phenylindole (DAPI)
(C1002, Beyotime Inst Biotech, China), and the num-
ber of cells on the lower surface of the filters was
counted under the microscope. A total of 5 fields were
counted for each transwell filter.
Western blotting analysis
Total proteins extracts of each group cells were resolved
by 10% SDS-PAGE and transferred on PVDF (Millipore)
membranes. After blocking, the PVDF membranes were
washed 4 times for 15 min with TBST at room tempera-
ture and incubated with primary antibody (rabbit anti-
human TP53INP1 polyclonal antibody; 1:1000, ab9775,
Abcam). Following extensive washing, membranes were
incubated with secondary peroxidase-linked goat anti-
rabbit IgG (1:1000, sc2030, Santa Cruz) for 1 h. After
washing 4 times for 15 min with TBST at room tem-
perature once more, the immunoreactivity was visua-
lized by enhanced chemiluminescence (ECL kit, Pierce
Biotechnology), and membranes were exposed to Kodak
XAR-5 films (Sigma-Aldrich).
Construction of reporter plasmids and luciferase assay
To construct a reporter plasmid containing the 3’UTR
of TP53INP1, 480 bp DNA fragment of partial 3’UTR of
TP53INP1 containing the wild-type 3’UTR of TP53INP1
or mutant 3’UTR of TP53INP1 was chemically synthe-
sized and cloned into the pMIR-REPORT luciferase vec-
tor (Ambion) downstream of the luciferase gene and
named pMIR-TP53INP1-3’UTR-WT and pMIR-
TP53INP1-3’UTR-MT, respectively. The nucleotide
sequences of the constructed plasmids were confirmed
by DNA sequencing analysis. All steps of luciferase
reporter assay were according to the previously
described [13,23]. NIH-3T3 cells(1 × 105) were seeded
into 24-well plates, and each was transfected with 0.5 μg
of either pMIR-TP53INP1-3’UTR-WT vector or pMIR-
TP53INP1-3’UTR-MT vector containing Firefly lucifer-
ase, together with 0.2 μg of the pRL-TK vector (Pro-
mega) containing Renilla luciferase and 50nM miR-
125bm, miR-125bm NC or none using the Lipofecta-
mine2000 transfection reagent according to the manu-
facturer’s protocol. After 48 h transfection, luciferase
activity was measured using the dual luciferase reporter
assay system (Promega). The results were expressed as
relative luciferase activity (Firely LUC/Renilla LUC).
Tumorigenicity assays in nude mice
All experimental protocols were approved by the Ethic
Committee for Animal Experimentation of Shanghai
Jiaotong University. A total of 5 × 106 cells suspended
in 100 μl 1× PBS were injected into the bilateral hind
leg subcutaneous tissue of four-week old female BALB/
C athymic nude mice. Three groups of mice (n = 12)
were tested. MiR-125b plasmid group was injected with
ishikawa cells transfected with miR-125b expression
plasmid. Control vector group was injected with
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ishikawa cells transfected with negative control plasmid.
During a five-week follow-up period, the sizes of tumors
were measured weekly. Mice were sacrificed at 42 days
post-injection. Tumors were excised and measured. The
short and long diameters of the tumors were measured
using a caliper and tumor volumes (cm3) were calcu-
lated by using the following standard formula: tumor
volumes (cm3) = (the longest diameter) × ( the shortest
diameter)2 × 0.5.
Immunohistochemistry
Tissues were fixed in 4% paraformaldehyde and
embedded in paraffin blocks. Sections (4 μm) were used
for immunohistochemical examination. Ki67 protein
expression of tumor tissues were detected using stan-
dard avidin-biotin immunohistochemical techniques
with use of an anti-ki67 antibody (1:100, lab vision, Fre-
mont, USA) according to the manufacturer’s instruc-
tions. The labeled cell nuclei in tumor sections were
regarded as positive. Proliferative tumor cells were
counted in 10 randomly different microscopic fields
respectively. The proliferative index was calculated as
follows: (number of positive tumor cells/number of total
tumor cells) × 100%.
Statistical analysis
Each experiment was performed as least three times,
and data are shown as the mean ± SD where applicable,
and differences were evaluated using one-way ANOVA
for 3-group comparisons and t tests for 2-group com-
parisons. All statistical analyses were performed using
SPSS 13.0 software package. The probability of P < 0.05
was considered to be statistically significant.
Results
Differential expression of miR-125b between type I and
type II EC cells
In our previous work, we found that miR-125b was sig-
nificantly overexpressed in type II EC cells (KLE and
AN3CA) with ER negative compared with type I EC
cells (RL95-2 and ishikawa) with ER positive using
microRNA microarray (unpublished data). To validate
microarray findings, TaqMan based qRT-PCR analysis
of differentially expressed miR-125b was performed. In
agreement with the microarray results, there was a sig-
nificant difference of miR-125b expression between ER-
negative and ER-positive cells (P < 0.01). As shown in
Figure 1A, the expression of miR-125b in KLE cells was
17.36 fold (p = 0.000) and 3.46 fold (p = 0.002) that of
RL95-2 and ishikawa, respectively; the expression of
miR-125b in AN3CA cells was 22.39 fold (p = 0.000)
and 4.46 fold (P = 0.000) that of RL95-2 and ishikawa,
respectively; the expression of miR-125b in ishikawa
cells was 5.03 fold ( p = 0.173) that of RL95-2. There
was a slight increase in expression of miR-125b in
AN3CA cells compared with KLE but with no statistical
significance. In addition, northern blotting revealed that
miR-125b signal in EC cells with ER negative was stron-
ger than in that with ER positive (Figure 1B).
MiR-125b promoted proliferation of EC cells
To investigate the biological effect of miR-125b, cell
proliferation was measured after differential transfection.
Transfection efficiency was detected at 72 h post-trans-
fection (Figure 2A and 2B). As shown in Figure 2C,
treatment with miR-125bm significantly stimulated the
growth of ishikawa cells compared with miR-125bm NC
and untransfected (Figure 2C, p < 0.05). MiR-125bi, but
not the miR-125bi NC significantly inhibited the growth
of AN3CA cells compared with untransfected group
(Figure 2D, p < 0.05).
MiR-125b enhanced the mobility of EC cells
To explore the roles of miR-125b in the regulation of
cell mobility, we examined the migration ability of ishi-
kawa and AN3CA cells after different transfection treat-
ment by using wound healing assay and transwell
migration assay, respectively. For wound healing assay,
ishikawa cells transfected with miR-125bm exhibited an
obvious increase in migration rate as compared to miR-
125bm NC or untransfected group; and ishikawa cells
transfected with miR-125bm, but not miR-125bm NC,
closed the wound at 48 h after incubation (Figure 3).
AN3CA cells without transfection or transfected with
miR-125bi NC nearly closed the wound at 48 h after
incubation, whereas AN3CA cells transfected with miR-
125bi were unable to close the wound at the same time
point (additional file 1).
In addition to wound healing assay, transwell migra-
tion assay was also performed to confirm the increase
Figure 1 Expression of miR-125b were assessed in EC cells by
qRT-PCR and Northern blotting. A. Differential expression of miR-
125b between type I and type II EC cells. Bars show mean ± SD. All
experiments were repeated three times. *P < 0.01 vs. ishikawa, KLE,
AN3CA. B. The results of Northern blotting show that the hybridized
signal of the mature miR-125b in EC cells with ER negative was
stronger than that in EC cells with ER positive.
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in motility of EC cells with overexpressed miR-125b.
Consistent with the results in wound healing, migra-
tion was significantly promoted in all three miR-125b
overexpressed EC cells (ishikawa transfected with
miR-125bm, AN3CA without treatment or transfected
with miR-125bi NC) (Figure 4A~D). The number of
migrated cells of ishikawa cells transfected with miR-
125bm was increased nearly 3.5 (or 2.5) fold as com-
pared with miR-125bm NC (or blank) (Figure 4A~B).
The number of migrated cells of AN3CA cells trans-
fected with miR-125bi was reduced about 2.5 fold as
compared with miR-125bi NC or blank (Figure
4C~D).
These results exhibit a functional role for miR-125b in
mediating migration in EC cells and suggest a mechan-
ism by which overexpression of miR-125b may contri-
bute to metastasis of type II EC.
MiR-125b negatively regulated the expression of
TP53INP1
To search for potential targets of miR-125b that may
influence proliferation, migration ability of cells, Tar-
getScan, Pictar-Vert, and Microrna.Org were employed
for this purpose. TP53INP1 was found among potential
targets of miR-125b combinational predicted by the
three softwares. The 3’UTR of TP53INP1 carries a
Figure 2 Analysis of transfection efficiency and cell proliferation after differential treatment. A. Transfection efficiency of ishikawa cells
was measured at 72 h after differential transfecton by qRT-PCR. Bars show mean ± SD. *P < 0.01 vs. miR-125bm NC, untransfected. B.
Transfection efficiency of AN3CA cells was measured at 72 h after differential transfecton using qRT-PCR. Bars show mean ± SD. *P < 0.01 vs.
miR-125bi NC, untransfected. C. CCK8 analysis of the growth of three groups of ishikawa cells. *P < 0.05 vs. miR-125b NC, untransfected. D. CCK8
analysis of the growth of three groups of AN3CA cells. *P < 0.05 vs. miR-125b NC, untransfected.
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binding site for miR-125b (Figure 5A), suggesting that
TP53INP1 mRNA might be a direct target of miR-125b.
We therefore evaluated the effect of miR-125b on the
expression of TP53INP1 protein in ishikawa (or
AN3CA) cells transfected with miR-125bm (or miR-
125bi). Transfection with miR-125bm led to nearly 65%
down-regulation of TP53INP1 in ishikawa cells com-
pared with miR-125bm NC or untransfected group,
whereas treatment with miR-125bi induced 167%
increase in the TP53INP1 in AN3CA cells, respectively
compared with miR-125bi NC (Figure 5B).
TargetScan analysis indicated that TP53INP1 contains
one miR-125b binding site on its 3’UTR, and the
sequence of the binding site is highly conserved across
different species (chimpanzee, Rhesus, Mouse, Rat, and
human) (Figure 5C). To verify that the putative miR-
125b binding site in the 3’UTR of TP53INP1 is respon-
sible for regulation by miR-125b, we constructed vectors
containing wild-type or mutant 3’UTR of TP53INP1
directly fused to the downstream of the Firefly luciferase
gene (Figure 5D). The wild-type or mutant vector was
cotransfected into NIH-3T3 cells with miR-125bm, miR-
125bm NC or none. The transfection efficiency was nor-
malized by cotransfection with Renilla reporter vector.
As shown in Figure 5E, miR-125b significantly decreased
the relative luciferase activity of wild-type TP53INP1
3’UTR (more than 60%), whereas the reduction of the
luciferase activity with mutant TP53INP1 3’UTR was
not as sharp as that observed in the wild-type counter-
part, suggesting that miR-125b could directly bind to
the 3’UTR of TP53INP1. Taken together, these findings
indicate that TP53INP1 is a direct downstream target
for miR-125b in EC cells.
The inhibition of the proliferation and migration of type
II EC cells by miR-125bi could be significantly attenuated
by the repressing of TP53INP1
To address whether the above-observed phenotype is
indeed due to the suppression of TP53INP1 and not
from the targeting of other cellular genes by miR-125b,
a rescue experiment was performed. We cotransfected
AN3CA cells with miR-125bi plus siTP53INP1
Figure 3 Effect of miR-125b on cell migration of AN3CA cells after differential treatment in vitro wound healing assay. Ishikawa cells
were seeded in 6-well plates and wounding on the next day. Photographs were taken at hour 0, 24, and 48 h, respectively, after the wound
was made. Ishikawa cells transfected with miR-125b, but not miR-125bm NC and untransfected group, closed the wound at 48 h after
incubation.
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Figure 5 MiR-125b negatively regulated TP53INP1 protein levels in EC cells. A. Putative binding sites of miR-125b in the TP53INP1 3’UTR
(white sequences) predicted by TargetScan. B. TP53INP1 protein levels were measured in EC cells at 72 h post-transfection by western blot
assays. C. Potential binding site of miR-125b on TP53INP1 3’UTR in different species. The seed sequence is underlined. D. Sketch of the
construction of pMIR-TP53INP1-3’UTR-WT or pMIR-TP53INP1-3’UTR-MT vectors. The mutant binding site is underlined and italicized. E. MiR-125bm
down-regulated luciferase activities controlled by wild-type TP53INP1 3’UTR, but did not affect luciferase activity controlled by mutant TP53INP1
3’UTR (white sequences were mutated). The results are means of three independent experiments ± SD. (**P < 0.01 vs. blank; #P > 0.05 vs. blank).
Figure 4 MiR-125b enhanced the mobility ability of EC cells using transwell migration assay. A. ishkawa cells were seeded in transwell
filter. Migrated cells on the lower surface of the transwell filter were stained and counted after 24 h. Photographs were taken at 24 h post-
migration (magnification, 100×). B. The numbers of migrated cells of ishikawa. Bars show mean ± SD. All experiments were repeated three times.
*P < 0.01 vs. miR-125bm NC, untransfected. C. AN3CA cells seeded in transwell filter. Migrated cells on the lower surface of the transwell filter
were stained and counted after 24 h. photographs were taken at 24 h post-migration (magnification, 100×). D. The numbers of migrated cells of
AN3CA. Bars show mean ± SD. All experiments were repeated three times. *P < 0.01 vs. miR-125bi NC, untransfected.
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(TP53INP1 siRNA) or with the same inhibitors plus siT-
P53INP1 control. At 48 h posttransfection, western blot
revealed that the expression level of TP53INP1 protein
in cells cotransfected with miR-125bi plus siTP53INP1
was significantly lower than that in cells cotransfected
with miR-125bi plus siTP53INP1 control (Figure 6A~B,
P < 0.01). Indeed, AN3CA cells with stably repressed
TP53INP1 were enhanced in both proliferation and
migration ability by using CCK8 and transwell migration
analysis respectively (Figure 6C, P < 0.05 and Figure 6D,
P < 0.01). These results imply that repressing TP53INP1
expression could significantly attenuate the inhibitory
effect of miR-125bi on cell proliferation and migration,
suggesting that the miR-125b promoted the proliferation
and migration of AN3CA cells through targeting
TP53INP1 signal pathway.
Oncogenic role of miR-125b was further demonstrated in
vivo tumor xenograft model
To further determine the role of miR-125b in the pro-
gression of EC, we did in vivo animal experiments using
ishikawa cells. Tumor formations were observed subcu-
taneously in all nude mice at 2 weeks after injection.
During a five-week follow-up period, it was observed
that the tumor volumes were increasing (Figure 7A). At
six weeks, the size and weights of tumors were substan-
tially larger in miR-125b plasmid group than those in
no transfection group and control vector group,
Figure 6 Repressing TP53INP1 could significantly attenuate the inhibitory effect of miR-125bi on type II EC cell proliferation and
migration. A~B. The expression level of TP53INP1 protein was detected by western blot at 48 h posttransfection and normalized to that of b-
actin. The expression level of TP53INP1 protein was significantly lower in cells cotransfected with miR-125bi plus siTP53INP1 as compared to the
cells cotransfected with the same inhibitors plus siTP53INP1 control (*P < 0.01). C. Cell proliferation was evaluated by CCK8 analysis. The
proliferative capacity of AN3CA cells cotransfected with miR-125bi plus siTP53INP1 was significantly higher than that of cells cotransfected with
miR-125bi plus siTP53INP1 control (*P < 0.05). D. Cell migration ability of AN3CA was determined by transwell migration analysis. The number of
migrated cells of AN3CA cells cotransfected with miR-125bi plus siTP53INP1 was increased about 2.5 fold as compared that of cells cotransfected
with miR-125bi plus siTP53INP1 control (*P < 0.01).
Jiang et al. BMC Cancer 2011, 11:425
http://www.biomedcentral.com/1471-2407/11/425
Page 8 of 12
respectively (Figure 7B~D). Furthermore, tumor tissues
were embedded in paraffin and then stained with hema-
toxylin and eosin (H&E) for histology examination (Fig-
ure 7E, upper panel). To observe the proliferation ability
of ishikawa cells, we performed immunohistochemical
staining of ki67, which was expressed as proliferation
index. Ki67 protein expression occurred in the nuclei of
the tumor cells (Figure 7E, lower panel). The prolifera-
tion indexes were (77.40 + 9.29) %, (34.00 +5.61) %, and
(35.60 +7.40) %, in miR-125b plasmid group, control
vector group, and no transfection group, respectively.
Compared with no transfection group and control vec-
tor group, miR-125b plasmid group had higher prolif-
eration indexes in xenograft tumor models (p < 0.01). In
addition, staining intensity of ki67 in miR-125b plasmid
group was much stronger than other groups.
Discussion
Overexpression of miR-125b has been observed in many
cancers such as prostate cancer [13], pancreatic cancer
[24], and oligodendroglial tumors [17]. Furthermore,
miR-125b plays a vital role in promoting the develop-
ment of precursor B-cell acute lymphoblastic leukemia
and prostate cancer [13,25]. These reports suggested
that miR-125b might be associated with tumorigenesis
of other types of human tumors. Consistent with these
published findings, our results support the concept that
miR-125b may act as an oncogene in type II EC. One
Figure 7 Tumorigenicity assay in nude mice. A. Tumor growth curve in nude mice. After tumor cells were injected subcutanecously into the
bilateral hind leg of nude mice, the short and long diameters of the tumors were measured weekly and tumor volumes (cm3) were calculated.
B. the nude mice with tumor formations. ① indicates the nude mouse injected with ishikawa cells transfected with miR-125b plasmid. ②
indicates the nude mouse injected with ishikawa cells transfected with control vector. ③ indicates the nude mouse injected with ishikawa cells
with no treatment. C. Photograph of tumors derived from miR-125b plasmid, control vector, or untransfected ishikawa cells in nude mice. D.
Weights of tumors. *P < 0.01 as compared with either no transfection group or control vector group. E. Representative HE staining
histopathologic image of tumor tissues in mice. (upper panel). ki67 expression of tumors was detected by immunohistochemical techniques
(lower panel).
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recent publication was about a comprehensive analysis
of the miRNA profile of surgically staged early and
advanced endometrial cancer using archival primary ECs
tissue samples, and found that expression of miR-125b-
1 and miR-125b-2 in stages III and IV ECs was 3.655
and 3.89 fold of stage I endometrioid ECs, respectively
[22]. Stages III and IV ECs mostly consist of type II
endometrial carcinomas including papillary serous carci-
noma and clear cell carcinomas. Previous profiles of
microRNAs were totally obtained from microRNAs
microarray of archived EC tissue samples, and there was
a disadvantage that the findings might be interfered
with mesenchymal cells and other non EC components.
To solve the problem, we are first, to our knowledge, to
choose well-differentiated EC cells with ER positive and
metastatic EC cells with ER negative as models of type I
and type II EC, respectively. Using microRNAs microar-
ray, we found that miR-125b was significantly overex-
pressed in type II EC cells with ER negative. Moreover,
qRT-PCR was further performed to demonstrate the
results of microRNAs microarray. Besides, in our prere-
searches, we detected endogenous TP53INP1 expression
on the archival paraffin-embedded EC specimens of
between type I (endometrioid) and type II (papillary ser-
ous) patients (each 10 cases) by immunohistochemistry
and found that TP53INP1 was expressed in 8/10 type I
EC and 1/10 type II EC (unpublished data). Meanwhile,
we selected significantly up-regulated miRNAs (n = 6,
miR-125b, miR-196b, miR-625, miR-196a*, miR-29a,
and miR-140-5P) in our microRNAs microarray (unpub-
lished data) and validated their expression in type I and
type II (each 10 cases) EC samples by qRT-PCR. We
found that endogenous miR-125b expression was the
most significantly up-regulated in type II EC samples
compared with type I (additional file 2). These results
suggested that the expression level of miR-125b was
inversely to endogenous TP53INP1 expression in EC I
vs. EC II primary tissues, although the number of the
samples is too small to reach a solid conclusion. Our
findings were consistent with a previous observation
that miR-125b was overexpressed in stages III and IV
ECs compared with stage I [22]. MiR-125b is dysregu-
lated in various human cancers but its underlying
mechanisms of action are poorly understood.
In current study, exogenous miR-125b expression sti-
mulated the growth and mobility of ishikawa cells,
whereas ablation of miR-125b inhibited the growth and
mobility of AN3CA cells in vitro. In addition, in vivo
xenograft experiment confirmed that forced miR-125b
expression promoted proliferation potential of EC cells.
We next asked how miR-125b might function inside
cells accounting for the effect of miR-125b on biological
behavior of EC cells. Using computational search, 148
potential targets of miR-125b were combinational
predicted by TargetScan, Pictar-Vert, and Microrna.Org
(additional file 3). Among 148 candidates, 4 are poten-
tial tumor suppressors including Bmf, adenomatous
polyposis coli (APC), START domain containing 13
(STARD13), and TP53INP1. Bmf and STARD13 mRNA
was not detectable in these EC cells. Aberrant APC
expression, involving WNT signal pathway, was scarcely
reported in publication about type II EC. Therefore, we
focused on TP53INP1 involving p53 signal pathways.
The main pathway alterations in type II ECs involve
p53 which, as a multifunctional transcription factor,
plays a central role in cell cycle regulation and genetic
stability. Over 90% type II ECs harbor mutant p53 with
loss of function [26,27]. TP53INP1 is a proapoptotic
stress-induced p53 target gene. It is a tumor suppressor
gene with a known role in cellular homeostasis through
its antiproliferative and proapoptotic activities via both
p53-dependent and p53-independent means [28,29].
However, in the absence of wild type p53 in type II ECs,
it may be more important for TP53INP1 to maintain
cell homeostasis. There is still no research about
TP53INP1 in ECs. However findings in recent years
have shown a significant reduction or loss of TP53INP1
expression during the development of cancers of the
breast [30], stomach [31], and pancreas [32]. Besides
TP53INP1 protein negativity was significantly associated
with aggressive pathological phenotypes of gastric can-
cer; and TP53INP1-positive rate decreased with the pro-
gression of gastric cancer [31]. These suggest that
TP53INP1 play an important role in suppression of
tumor progression [31-34]. MicroRNAs are estimated to
regulate the expression of over 30% genes and their
functions [35,36], suggesting a possibility that some spe-
cific microRNAs might directly regulate TP53INP1.
With respect to miRNAs which may regulate the
expression of TP53INP1, several studies had reported
that TP53INP1 was repressed by miR-155 in pancreatic
cancer [32] and miR-130b in hepatocelluar cancer [37],
respectively. However, miR-155 and 130b were not
among differential expression miRNAs profiles in our
studies. In present study, we newly identified miR-125b
as the direct regulator of TP53INP1. MiR-125b can
directly repress the TP53INP1 protein expression
through its binding to the binding sites in 3’UTR of
human TP53INP1 gene, thereby negatively regulating
TP53INP1 functions. In addition to TP53INP1, three
recent studies reported miR-125b can directly target p53
[18], Bak1 [19], and Bmf [20] to enhance the initiation
and progression of tumor. Thus, miR-125b might have
many other targets that remain to be discovered in
future.
The findings here show a regulatory interaction
between miR-125b and the tumor suppressor protein,
TP53INP1. The results agree with observations
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elsewhere that aberrant loss of TP53INP1 correlates
with the proliferation and migration, but not metastasis
[37,38]. This study not only will allow for better under-
standing of mechanisms which contributes to malig-
nancy of type II ECs, but also will provided sight into
the gradual importance of more effective cancer thera-
pies against this disease.
Although some of the results presented here are novel,
this study has some limitations. Firstly, the number of
the cells line is too small to reach a solid conclusion. In
addition, it is required further to evaluate the expression
of TP53INP1 and miR-125b simultaneously in large type
II EC tissue samples.
Conclusions
In present studies, we found that miR-125b was overex-
pressed cultured type II EC cells compared with type I.
exogenous miR-125b expression stimulated the growth
and mobility of ishikawa cells, whereas ablation of miR-
125b inhibited the growth and mobility of AN3CA cells
in vitro. In addition, in vivo tumor formation assay con-
firmed that forced miR-125b expression promoted pro-
liferation potential of EC cells. Tumor suppressor gene
TP53INP1 was newly identified to be the direct down-
stream target of miR-125b. MiR-125b contributes to
malignancy of type II EC possibly through down-regu-
lating TP53INP1.
Additional material
Additional file 1: Effect of miR-125b on cell migration of AN3CA
cells after differential treatment in vitro wound healing assay.
AN3CA cells were seeded in 6-well plates and wounding on the next
day. Photographs were taken at hour 0, 24, and 48 h, respectively, after
the wound was made. AN3CA cells without transfection and transfected
with miR-125bi NC nearly closed the wound at 48 h after incubation,
whereas AN3CA cells transfected with miR-125bi were unable to close
the wound at the same time point.
Additional file 2: Endogenous miR-125b expression was the most
significantly up-regulated in type II EC samples compared with type
I. QRT-PCR was performed to validate the expression of endogenous
miRNAs (n = 6, miR-125b, miR-196b, miR-625, miR-196a*, miR-29a, and
miR-140-5P), which were significantly up-regulated in our microRNAs
microarray, in type I (endometrioid) and type II (papillary serous) EC
samples. The results showed that endogenous miR-125b expression was
the most significantly up-regulated in type II EC samples compared with
type I.
Additional file 3: Shown are 148 potential targets of miR-125b
which were combinational predicted by TargetScan, Pictar-Vert, and
Microrna.Org.
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